At CNBC Cures, Becky Quick Leads Clarion Call for Rare Disease Research

Why It Matters

Without updated regulations and payer models, the unprecedented pace of rare‑disease innovation cannot translate into accessible treatments, limiting both patient outcomes and market growth.

Key Takeaways

• Rare disease breakthroughs outpace outdated regulatory frameworks.
• AI promises to cut diagnostic odyssey from years to months.
• Patient-led foundations derisk early research and attract biotech partners.
• Stable, bipartisan policy needed for long‑term drug development investments.
• Affordability and access remain critical barriers despite scientific progress.

Pulse Analysis

The CNBC Cures Summit in New York gathered regulators, biotech CEOs, investors, and parent‑advocates to confront a fundamental mismatch: scientific tools for rare diseases are evolving faster than the policies that govern them. Gene‑editing platforms, antisense oligonucleotides, and modular “nodal biology” approaches promise to treat multiple conditions with a single therapeutic component. Yet former FDA Commissioner Scott Gottlieb warned that the agency’s review capacity has not kept pace, creating bottlenecks that delay life‑saving approvals. Modernizing trial designs—standardized endpoints, real‑world data integration, and accelerated pathways—emerges as a top priority for sustaining industry investment.

Artificial intelligence is poised to reshape the diagnostic odyssey that currently averages seven years for rare‑disease patients. By aggregating global genomic, clinical, and patient‑reported data, AI can flag pathogenic variants and suggest therapeutic targets far more quickly than traditional methods. Fidji Simo’s remarks at the summit highlighted AI’s role as a catalyst rather than a replacement for scientific discovery, potentially shrinking time‑to‑treatment and lowering development costs. Simultaneously, patient‑driven organizations like the Foundation for Angelman Syndrome Therapeutics demonstrate how families can de‑risk early research, attract biotech partnerships, and accelerate clinical translation, turning personal urgency into structured innovation pipelines.

Policy and payer dynamics remain the final hurdle. Congressional voices emphasized the need for bipartisan, long‑term commitments to ensure that regulatory certainty matches the 10‑ to 20‑year horizons of biotech investments. Insurance structures, however, still struggle to reconcile high‑cost gene therapies with affordable coverage, as illustrated by the controversy surrounding Sarepta’s Elevidys. Aligning intellectual‑property protections, value‑based pricing, and transparent reimbursement frameworks will be crucial to prevent breakthroughs from becoming financially inaccessible. The summit’s consensus: scientific possibility is abundant, but only coordinated regulatory, economic, and patient‑centered reforms will unlock its full potential for millions living with rare diseases.